Tiziana Life Sciences: CEO Update on Spinoff and New COVID-19 Trial
Sep. 23, 2020
Tiziana Life Sciences (NASDAQ: TLSA) CEO & CSO, Dr. Kunwar Shailubhai, discusses the Company’s planned spinoff of StemPrintER and the launch of its new COVID-19 trial in Brazil. Tiziana is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio. Visit TLSAinfo.com to learn more.
